Abstract
[This corrects the article DOI: 10.18632/oncotarget.23675.].
Highlights
There are 112 advanced stage female genital tract cancer patients described within this resource, and we mined this cohort after web scraping the data, to assess how much tumor profiling recommendations were used in drug selection by clinicians, and if any molecular subsets had different outcomes
The longest time of monitoring after profiling was 1366 days which was 1440 days after diagnosis
ION data is covered under an IRB exemption
Summary
This article has been corrected: The proper Materials and Methods and Conflicts of Interest information is as follows: MATERIALS AND METHODS. Correction: Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy The Caris CODE database (Comprehensive Oncology Database Explorer) version 1.0 contains tumor molecular profile data for 841 patients with solid tumors.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
